Poor anticoagulant response to tissue factor pathway inhibitor in patients with venous thrombosis.
Tissue factor pathway inhibitor (TFPI) is of major importance in regulating the coagulation triggering effects of tissue factor. An association between TFPI deficiency and thrombosis has still not been clearly demonstrated. We evaluated the anticoagulant activity of exogenous TFPI added either to the plasma of patients with venous thrombosis (n = 118) or to the plasma of healthy controls similar in terms of mean age and sex ratio (n = 107). A poor anticoagulant response to TFPI, defined as TFPI resistance, was observed in 4.7% of controls and in 11.0% of patients. TFPI resistance was associated with an almost threefold increase in the risk of thrombosis and could therefore represent a novel hemostatic risk factor for venous thrombosis.
Tardy-Poncet
B
B
Laboratoire d'Hématologie, Hôpital Nord, France. brigitte.tardy@chu-st-etienne.fr
Tardy
B
B
Laporte
S
S
Mismetti
P
P
Amiral
J
J
Piot
M
M
Reynaud
J
J
Campos
L
L
Decousus
H
H
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D016022:Case-Control Studies; D004351:Drug Resistance; D005192:Family Health; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012307:Risk Factors; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology*
D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor